Total Payments
$128,709
2024 Payments
$28,527
Companies
12
Transactions
113
Medicare Patients
50
Medicare Billing
$3,617
Payment Breakdown by Category
Consulting$86,955 (67.6%)
Travel$23,768 (18.5%)
Other$14,033 (10.9%)
Research$2,478 (1.9%)
Food & Beverage$1,471 (1.1%)
Education$2.66 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $86,955 | 33 | 67.6% |
| Travel and Lodging | $23,768 | 33 | 18.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,033 | 4 | 10.9% |
| Unspecified | $2,478 | 8 | 1.9% |
| Food and Beverage | $1,471 | 34 | 1.1% |
| Education | $2.66 | 1 | 0.0% |
Payments by Type
General
$126,230
105 transactions
Research
$2,478
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $62,069 | 34 | $0 (2024) |
| Otsuka Pharmaceutical Co., Ltd. | $23,754 | 27 | $0 (2019) |
| Otsuka America Pharmaceutical, Inc. | $14,942 | 18 | $0 (2024) |
| GENZYME CORPORATION | $12,676 | 9 | $0 (2021) |
| VERTEX PHARMACEUTICALS INCORPORATED | $6,984 | 9 | $0 (2024) |
| SANOFI US SERVICES INC. | $6,083 | 7 | $0 (2018) |
| Janssen Research & Development, LLC | $1,215 | 1 | $0 (2023) |
| ZOLL Medical Corporation | $508.33 | 1 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $344.85 | 1 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $127.27 | 4 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $28,527 | 19 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($18,636) |
| 2023 | $5,638 | 6 | Otsuka America Pharmaceutical, Inc. ($2,550) |
| 2022 | $3,837 | 6 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($3,706) |
| 2021 | $17,343 | 7 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($14,989) |
| 2020 | $15,107 | 10 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($10,170) |
| 2019 | $29,389 | 32 | Otsuka Pharmaceutical Co., Ltd. ($23,754) |
| 2018 | $14,879 | 13 | Otsuka America Pharmaceutical, Inc. ($9,883) |
| 2017 | $13,989 | 20 | Otsuka Pharmaceutical Development & Commercialization, Inc. ($9,703) |
All Payment Transactions
113 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/08/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Travel and Lodging | Cash or cash equivalent | $61.80 | General |
| Category: NEPHROLOGY | ||||||
| 10/08/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Travel and Lodging | Cash or cash equivalent | $49.78 | General |
| Category: NEPHROLOGY | ||||||
| 10/08/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Food and Beverage | Cash or cash equivalent | $19.24 | General |
| Category: NEPHROLOGY | ||||||
| 10/03/2024 | Otsuka Pharmaceutical Development & Commercialization, Inc. | TOLVAPTAN (Drug) | Consulting Fee | Cash or cash equivalent | $18,505.50 | General |
| Category: NEPHROLOGY | ||||||
| 09/11/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $6,815.85 | General |
| 08/26/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Travel and Lodging | In-kind items and services | $303.97 | General |
| Category: NEPHROLOGY | ||||||
| 08/26/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $52.60 | General |
| Category: NEPHROLOGY | ||||||
| 08/26/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $43.78 | General |
| Category: NEPHROLOGY | ||||||
| 08/26/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Travel and Lodging | In-kind items and services | $38.99 | General |
| Category: NEPHROLOGY | ||||||
| 08/26/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Travel and Lodging | In-kind items and services | $30.48 | General |
| Category: NEPHROLOGY | ||||||
| 08/25/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Travel and Lodging | In-kind items and services | $391.79 | General |
| Category: NEPHROLOGY | ||||||
| 08/25/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $35.45 | General |
| Category: NEPHROLOGY | ||||||
| 08/12/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Consulting Fee | Cash or cash equivalent | $1,074.40 | General |
| Category: NEPHROLOGY | ||||||
| 07/26/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Food and Beverage | In-kind items and services | $33.89 | General |
| 07/26/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Food and Beverage | In-kind items and services | $27.55 | General |
| 07/26/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Food and Beverage | In-kind items and services | $14.61 | General |
| 07/26/2024 | VERTEX PHARMACEUTICALS INCORPORATED | — | Food and Beverage | In-kind items and services | $9.46 | General |
| 05/07/2024 | ZOLL Medical Corporation | Defibrillator (Device) | Consulting Fee | Cash or cash equivalent | $508.33 | General |
| Category: Resuscitation | ||||||
| 04/08/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Consulting Fee | Cash or cash equivalent | $510.00 | General |
| Category: NEPHROLOGY | ||||||
| 12/05/2023 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Consulting Fee | Cash or cash equivalent | $1,360.00 | General |
| Category: NEPHROLOGY | ||||||
| 12/01/2023 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $2.66 | General |
| 10/05/2023 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Consulting Fee | Cash or cash equivalent | $1,190.00 | General |
| Category: NEPHROLOGY | ||||||
| 05/15/2023 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,215.00 | General |
| 04/25/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | JYNARQUE (Drug) | Consulting Fee | Cash or cash equivalent | $680.00 | General |
| Category: NEPHROLOGY | ||||||
| 02/08/2023 | Otsuka Pharmaceutical Development & Commercialization, Inc. | JYNARQUE (Drug) | Consulting Fee | Cash or cash equivalent | $1,190.00 | General |
| Category: NEPHROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Multicenter, randomized, double-blind, placebo-controlled two stage study to characterize the efficacy, safety, tolerability and pharmacokinetics of GZ/SAR402671 in patients at risk of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPK | GENZYME CORPORATION | $1,288 | 2 |
| A PHASE 3B, MULTI-CENTER, OPEN-LABEL TRIAL TO EVALUATE THE LONG TERM SAFETY OF TITRATED IMMEDIATE-RELEASE TOLVAPTAN OPC-41061, 30 MG TO 120 MGDAY, SPLIT DOSE IN SUBJECTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $516.97 | 2 |
| Multicenter, randomized, double-blind, placebo-controlled two stage study to characterize the efficacy, safety, tolerability and pharmacokinetics of GZ/SAR402671 in patients at risk of rapidly progres | GENZYME CORPORATION | $509.62 | 2 |
| EFFICACY AND SAFETY OF TOLVAPTAN IN SUBJECTS WITH CHRONIC KIDNEY DISEASE BETWEEN LATE STAGE 2 TO EARLY STAGE 4 DUE TO AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE | Otsuka Pharmaceutical Development & Commercialization, Inc. | $163.41 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 2 | 50 | 61 | $16,613 | $3,617 |
Total Patients
50
Total Services
61
Medicare Billing
$3,617
Procedure Codes
2
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 39 | 50 | $15,227 | $2,855 | 18.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 11 | 11 | $1,386 | $762.23 | 55.0% |
About Dr. Ronald Perrone, MD
Dr. Ronald Perrone, MD is a Nephrology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1265541155.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ronald Perrone, MD has received a total of $128,709 in payments from pharmaceutical and medical device companies, with $28,527 received in 2024. These payments were reported across 113 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($86,955).
As a Medicare-enrolled provider, Perrone has provided services to 50 Medicare beneficiaries, totaling 61 services with total Medicare billing of $3,617. Data is available for 1 year (2020–2020), covering 2 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Boston, MA
- Active Since 08/30/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1265541155
Products in Payments
- TOLVAPTAN (Drug) $45,442
- JYNARQUE (Drug) $28,652
- SAMSCA (Drug) $23,754
- NO PRODUCT DISCUSSED (Drug) $6,205
- FABRAZYME (Drug) $5,264
- Defibrillator (Device) $508.33
- GZ402671 (Drug) $344.85
- TREMFYA (Drug) $28.89
- INVOKANA (Drug) $24.66
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Boston
David Friedman, M.d, M.D
Nephrology — Payments: $20.3M
Nephrology $20.3M
Martin Pollak, Md, MD
Nephrology — Payments: $20.3M
Nephrology $20.3M
Dr. Dennis Ausiello, Md, MD
Nephrology — Payments: $4.4M
Nephrology $4.4M
Dr. Ajay Singh, Md, MD
Nephrology — Payments: $1.2M
Nephrology $1.2M
Dr. Leslie Fang, Md, MD
Nephrology — Payments: $795,357
Nephrology $795,357
Dr. Jean Francis, M.d, M.D
Nephrology — Payments: $217,413
Nephrology $217,413